Journal
CANCERS
Volume 13, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cancers13061373
Keywords
biomarkers; exosome; extracellular vesicles; lung cancer; miRNA; plasma; serum
Categories
Funding
- National Science Centre, Poland [2017/27/B/NZ7/01833]
Ask authors/readers for more resources
Exosomes are emerging as a potential source of cancer biomarkers, particularly through the miRNA content. Despite promising research results, no biomarkers for early cancer detection have been clinically validated yet. This highlights the constant need for new biomarker candidates in the field of lung cancer research.
Simple Summary Exosomes are an emerging source of cancer biomarkers. Molecular components of serum-derived exosomes have been addressed in several reports in the context of biomarkers for early detection of lung cancer. However, despite the promising results of pilot studies, the clinical applicability of such biomarkers has not been validated yet. In this review, the diagnostic potential of miRNA content of serum-derived exosomes is presented. Moreover, potential target genes and signaling pathways affected by miRNA present in lung cancer signatures are discussed. Early detection of lung cancer in screening programs is a rational way to reduce mortality associated with this malignancy. Low-dose computed tomography, a diagnostic tool used in lung cancer screening, generates a relatively large number of false-positive results, and its complementation with molecular biomarkers would greatly improve the effectiveness of such programs. Several biomarkers of lung cancer based on different components of blood, including miRNA signatures, were proposed. However, only a few of them have been positively validated in the context of early cancer detection yet, which imposes a constant need for new biomarker candidates. An emerging source of cancer biomarkers are exosomes and other types of extracellular vesicles circulating in body fluids. Hence, different molecular components of serum/plasma-derived exosomes were tested and showed different levels in lung cancer patients and healthy individuals. Several studies focused on the miRNA component of these vesicles. Proposed signatures of exosome miRNA had promising diagnostic value, though none of them have yet been clinically validated. These signatures involved a few dozen miRNA species overall, including a few species that recurred in different signatures. It is worth noting that all these miRNA species have cancer-related functions and have been associated with lung cancer progression. Moreover, a few of them, including known oncomirs miR-17, miR-19, miR-21, and miR-221, appeared in multiple miRNA signatures of lung cancer based on both the whole serum/plasma and serum/plasma-derived exosomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available